Systemic Onset Juvenile Idiopathic Arthritis
Links shared publicly online about this topic
Canakinumab Relieves Symptoms In Systemic Juvenile Idiopathic Arthritis
medicalnewstoday.com — “Canakinumab (ACZ885; Novartis) achieves major relief of symptoms in patients with systemic juvenile idiopathic arthritis (SJIA), according to encouraging results from a pivotal phase III trial wit” View full resource at medicalnewstoday.com
Most Recently Shared on September 18, 2011 at 6:05 pm By:
MNT Arthritis News Health News
Canakinumab Relieves Symptoms In Systemic Juvenile Idiopathic Arthritis http://mnt.to/3ZJw #arthritis
RxEconsult, LLC - Actemra for rheumatoid arthritis and systemic juvenile idiopathic arthritis
rxeconsult.com — “RxEconsult, LLC - Actemra for rheumatoid arthritis and systemic juvenile idiopathic arthritis” View full resource at rxeconsult.com
Most Recently Shared on October 18, 2011 at 3:02 am By:
RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication." /> Ome Ogbru, PharmD Active Health Library, Doctor, Pharmacist, and PharmD
#Actemra for rheumatoid #arthritis and systemic juvenile idiopathic arthritis http://t.co/zPw6uiBI #Medications #healthcare
Phase 3 Study of ACZ885 for Children with Systemic Juvenile Idiopathic Arthritis - MPR
empr.com — “Novartis announced data from its Phase 3 study of ACZ885 (canakinumab) for the treatment of children with active systemic juvenile idiopathic arthritis (SJIA).” View full resource at empr.com
Most Recently Shared on November 7, 2011 at 6:10 pm By:
Phase 3 Study of ACZ885 for Children with Systemic Juvenile Idiopathic #Arthritis http://t.co/YQOHIojR
Rheumatology Article | Systemic juvenile idiopathic arthritis
mdlinx.com — “Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopathic arthritis complicated by macrophage activation syndrome” View full resource at mdlinx.com
Most Recently Shared on July 15, 2011 at 10:52 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Monitoring serum IL-18 levels is useful for treatment of a patient with systemic juvenile idiopath... http://bit.ly/nkGkuJ #Rheumatology
Rheumatology Medical News about Arthritis, Juvenile Rheumatoid Macrophage Activation Macrophage Activation Syndrome
mdlinx.com — “Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage activation syndrome with particular emphasis on the role of interleukin-18 in its pathogenesis” View full resource at mdlinx.com
Most Recently Shared on May 21, 2010 at 6:47 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Distinct cytokine profiles of systemic-onset juvenile idiopathic arthritis-associated macrophage acti... http://bit.ly/brt6ps #Rheumatology
Rheumatology Article | Juvenile idiopathic arthritis
mdlinx.com — “Pathogenesis of systemic juvenile idiopathic arthritis” View full resource at mdlinx.com
Most Recently Shared on June 21, 2011 at 9:13 pm By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Pathogenesis of systemic juvenile idiopathic arthritis: Nature Reviews Rheumatology http://bit.ly/l4IxI6 #Rheumatology
Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis - MPR
empr.com — “The FDA has approved Actemra (tocilizumab; Genentech), given alone or in combination with methotrexate, for the treatment of active systemic juvenile idiopathic arthritis (SJIA), or Still--™s disease, in children 2 years.” View full resource at empr.com
Most Recently Shared on April 18, 2011 at 4:11 pm By:
MPR News: Actemra Gains Approval for Systemic Juvenile Idiopathic Arthritis: The FDA has approved Actemra (tocil... http://bit.ly/erCY89
Novel System Reliable for Scoring MRIs in Juvenile Arthritis : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on December 23, 2010 at 6:13 pm By:
Bob Finn - Medical News Net Health News
For juvenile idiopathic arthritis, MRI scoring system for adults shown to work in kids too. Denise Napoli reports. http://bit.ly/giSE0M
Big Changes in Treatment of Systemic Juvenile Idiopathic Arthritis : Internal Medicine News
internalmedicinenews.com — “Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers all areas of internal medicine including adolescent medicine; cardiovascular disease; dermatology; diabetes, endocrinology and metabolism; gastroenterology; geriatric medicine; infectious diseases; mental health; oncology and hematology; nephrology and urology; neurology; pulmonary disease and sleep medicine; practice tre” View full resource at internalmedicinenews.com
Most Recently Shared on February 14, 2011 at 4:49 pm By:
Bob Finn - Medical News Net Health News
Treatment of juvenile idiopathic arthritis (JIA) is being flipped on its head. Bruce Jancin reports. http://bit.ly/fyPosX
Family Medicine Article | Arthritis, Juvenile Rheumatoid
mdlinx.com — “Predictors of Hip Disease in the Systemic Arthritis Subtype of Juvenile Idiopathic Arthritis” View full resource at mdlinx.com
Most Recently Shared on February 8, 2011 at 6:05 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Predictors of Hip Disease in the Systemic Arthritis Subtype of Juvenile Idiopathic Arthritis: Journ... http://bit.ly/hPn639 #FamPractice
Juvenile Arthritis (Juvenile Rheumatoid Arthritis) Symptoms, Causes, Treatment - What is the outlook (prognosis) for children with arthritis on MedicineNet
medicinenet.com — “Read about juvenile arthritis (juvenile rheumatoid arthritis, JRA) symptoms, treatment, diagnosis, prognosis, types (systemic-onset, pauciarticular, polyarticular) and causes.” View full resource at medicinenet.com
Most Recently Shared on August 4, 2010 at 7:48 pm By:
Susan Scroggins Active Health Library and Health Advocate
JRA is the most common type of arthritis affecting children. Learn more about this disease: http://bit.ly/9AcqT1
Rheumatology Medical News about Arthritis Arthritis, Juvenile Rheumatoid
mdlinx.com — “Development and initial validation of a radiographic scoring system for the hip in juvenile idiopathic arthritis” View full resource at mdlinx.com
Most Recently Shared on December 24, 2009 at 9:17 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Rheum: Development and initial validation of a radiographic scoring system for the hip in juvenile idiopathic arthritis: http://url4.eu/yVY6
Rheumatology Article | Arthritis
mdlinx.com — “Safety and efficacy of an oral histone deacetylase inhibitor in systemic onset juvenile idiopathic arthritis” View full resource at mdlinx.com
Most Recently Shared on January 22, 2011 at 1:12 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Safety and efficacy of an oral histone deacetylase inhibitor in systemic onset juvenile idiopathic... http://bit.ly/hkON1M #Rheumatology
Family Medicine Article | Arthritis
mdlinx.com — “Safety and efficacy of an oral histone deacetylase inhibitor in systemic onset juvenile idiopathic arthritis” View full resource at mdlinx.com
Most Recently Shared on January 21, 2011 at 7:05 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Safety and efficacy of an oral histone deacetylase inhibitor in systemic onset juvenile idiopathic ... http://bit.ly/dQZZP5 #FamPractice
Allergy/Imm Medical News about Arthritis, Juvenile Rheumatoid
mdlinx.com — “Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis” View full resource at mdlinx.com
Most Recently Shared on July 10, 2010 at 12:00 am By:
Sandeep Pulim MD Doctor, Health Communicator, and Physician
Monocytes are resistant to apoptosis in systemic juvenile idiopathic arthritis: Clinical Immunology http://bit.ly/cb9kVm #AI #mdlinx
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MNT Arthritis News
The latest arthritis / rheumatology news published daily. Articles from research centers, universities and prestigious journals.
-
RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication." />Ome Ogbru, PharmD
Dr. Ome Ogbru is the founder of RxEconsult, which is a social network for healthcare consulting, healthcare jobs, healthcare professionals, healthcare small businesses, life scientists, health information, and more. Members have profiles with details about their services on RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication. -
MPR
eMPR.com provides up-to-date, concise drug information at the point-of-care.
Advertisement
